Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | UNG | P13051 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | FBP1 | P09467 | 2/20 | 0.34 |
| ▸ | PTPRC | P08575 | 1/20 | 0.34 |
| ▸ | PTPRG | P23470 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30688451 | 1.00 | FFAR1 (0.50) | FFAR1ASIC3ALDH1A1UNGEGFR | |
| SCHEMBL2560355 | 0.86 | FFAR1 (0.52) | FFAR1ALDH1A1UNGEGFRSRC | |
| SCHEMBL29622517 | 0.86 | FFAR1 (0.52) | FFAR1ALDH1A1UNGEGFRSRC | |
| SCHEMBL9559955 | 0.82 | FFAR1 (0.52) | FFAR1ALDH1A1UNGHTR2CHTR2B | |
| SCHEMBL493774 | 0.81 | FFAR1 (0.45) | FFAR1ALDH1A1 | |
| SCHEMBL10633500 | 0.80 | FFAR1 (0.58) | FFAR1ALDH1A1UNGSRCTRIM24 | |
| SCHEMBL9700186 | 0.80 | KCNH2 (0.45) | FFAR1ALDH1A1 | |
| SCHEMBL2562582 | 0.79 | HRH3 (0.40) | FFAR1ALDH1A1EGFRPTPRCPTPRG | |
| SCHEMBL7680519 | 0.78 | KCNH2 (0.48) | FFAR1ALDH1A1 | |
| SCHEMBL10795164 | 0.78 | KCNH2 (0.48) | FFAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024531-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024531-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024531-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| CN-111491939-B | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230133165-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133165-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133165-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2023-05-04 | — | — | US | disclosed |
| EP-3710457-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-3710457-A1 | IMMUNOPROTEASOME INHIBITORS | Principia Biopharma, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-111491939-A | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20070072837-A1 | Phenylalkynes | APODACA RICHARD | 2007-03-29 | — | — | US | disclosed |
| US-20060258859-A1 | Phenylalkynes | APODACA RICHARD | 2006-11-16 | — | — | US | disclosed |
| EP-1567494-A1 | METHODS FOR PREPARING PHENYLALKYNE DERIVATIVES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-6884803-B2 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-04-26 | — | — | US | disclosed |
| EP-1451167-A1 | PHENYLALKYNES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2004050623-A1 | METHODS FOR PREPARING PHENYLALKYNE DERIVATIVES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040002604-A1 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-01-01 | — | — | US | disclosed |
| US-20030144323-A1 | For treatment of disorders and conditions mediated by the histamine receptor; allergies, sleep disorders, dementia | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-07-31 | — | — | US | disclosed |
| WO-2003050099-A1 | PHENYLALKYNES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| EP-0503079-A1 | PYRIDAZINONE-SUBSTITUTED ETHYNYLPHENYL DERIVATIVE AND REMEDY FOR CIRCULATORY ORGAN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258859-A1 | Phenylalkynes | HRH2, HRH3, HNMT | FFAR1 538/4885ASIC3 1203/4885ALDH1A1 207/4885 |
| US-12024531-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | FFAR1 4739/4885ASIC3 4210/4885ALDH1A1 3436/4885 |
| US-20230133165-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | FFAR1 4739/4885ASIC3 4210/4885ALDH1A1 3436/4885 |
| US-20070072837-A1 | Phenylalkynes | HRH2, HRH3, HNMT | FFAR1 538/4885ASIC3 1203/4885ALDH1A1 207/4885 |
| US-20030144323-A1 | For treatment of disorders and conditions mediated by the histamine receptor; allergies, sleep disorders, dementia | HRH3, HRH2, HRH4 | FFAR1 342/4885ASIC3 1625/4885ALDH1A1 1479/4885 |
| US-20040002604-A1 | Phenylalkynes | HRH2, HRH3, HNMT | FFAR1 538/4885ASIC3 1203/4885ALDH1A1 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.